CureApp, Inc. and Sawai Group Holdings Co., Ltd. enter into a development and marketing license agreement for a DTx*1 solution in the NASH field
CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake, hereafter, “the Company”) entered into a license agreement with Sawai Group Holdings Co., Ltd. (Head Office: Yodogawa-ku, Osaka; Representative Director and President: Kazuhiko Sueyoshi, hereafter, “the Sawai Group”) for the development and marketing of a DTx solution (hereafter, “the app”) in the NASH (Non-Alcoholic Steatohepatitis) field. With the conclusion of this agreement, the Sawai Group obtains exclusive rights concerning the development and marketing of the app indicated for the treatment of NASH. Under this agreement, the Company is set to receive up to 10.5 billion yen in total in the form of a lump sum contractual payment, and as additional payments for milestones reached based on future clinical development progress and sales targets. After launch, the Company plans to introduce the app at medical institutions via its proprietary app prescription service (APS). *1 Abbreviation of Digital Therapeutics. Softwa